We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 57

China issues revised draft regulations on monopoly agreements and abuses of dominant market position for second-round comments

  • McDermott Will & Emery
  • -
  • China
  • -
  • June 4 2010

The deadline for submission of comments on the new draft regulations is 7 June 2010

China aims to strengthen the protection of consumers’ personal information

  • McDermott Will & Emery
  • -
  • China
  • -
  • June 6 2013

The Standing Committee of the National People's Congress recently issued a draft amendment that would update China's 20-year-old Consumer Protection

New Chinese health and pharmaceuticals regulations

  • McDermott Will & Emery
  • -
  • China
  • -
  • June 28 2010

Regulation by the Chinese Government of the health and pharmaceuticals industry generally follows a cyclical pattern: a major incident occurs that impacts the Chinese public and triggers government investigations, resulting in changes to the regulation or regulatory system to close the loopholes found in the old legal regime that allowed the incident to happen in the first place

SEC, DOJ continue to enforce FCPA cases involving China and joint ventures

  • McDermott Will & Emery
  • -
  • China, USA
  • -
  • January 14 2011

China's reputation as an emerging world economy has garnered the attention of US law enforcement, including the US Securities and Exchange Commission and the US Department of Justice, which has increased its prosecution of violations of the Foreign Corrupt Practices Act

Whistleblowing in China and the United States

  • McDermott Will & Emery
  • -
  • China, USA
  • -
  • August 29 2013

Recent events in China underscore the importance of dealing effectively with whistleblowers. The Chinese Government's wide-ranging bribery and

China’s MOFCOM gets tough on merger control?

  • McDermott Will & Emery
  • -
  • China
  • -
  • June 17 2011

There is considerable speculation in China that many large transactions that should have been notified for clearance by China’s Ministry of Commerce (MOFCOM) have not been properly notified, and Chinese government is going to go after the concerned concentrating parties

China cracks down on commercial bribery to make medical products more affordable

  • McDermott Will & Emery
  • -
  • China
  • -
  • July 6 2009

In China, bribes are sometimes offered and accepted for the sale and procurement of pharmaceuticals, medical devices and medical paraphernalia (health care products

China improves clinical trials and speeds up drug licensing

  • McDermott Will & Emery
  • -
  • China
  • -
  • April 5 2012

With increasing investment in research and development by foreign companies in China, assuring the reliability and efficiency of the drug and device development process is a critical priority

When is resale price maintenance legal in China?

  • McDermott Will & Emery
  • -
  • China
  • -
  • July 5 2012

A Shanghai court recently decided the first case involving vertical monopoly agreements (i.e., between supplier and distributor) since China’s Anti-Monopoly Law (AML) came into effect in 2008

Chinese government issues Finalized Guidelines on Relevant Market Definition

  • McDermott Will & Emery
  • -
  • China
  • -
  • August 31 2009

On May 24, 2009, the Anti-Monopoly Committee of the State Council issued the finalized Guidelines on Relevant Market Definition (Guidelines